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ABSTRACT
Cerebral palsy is one of the leading developmental disabilities amongst children.
The majority of children with cerebral palsy experience some degree of spasticity. This
spasticity can be very painful and disabling to the child. It can affect their posture,
movements, and their mobility
Currently, baclofen is one of the most common medications used for the treatment
of cerebral spasticity. It can be administered either orally or intrathecally through an
implanted pump.
The purpose of this literature review is to discuss the use of oral and intrathecal
baclofen in the management of spasticity in children with cerebral palsy. Included is a
discussion about cerebral palsy and the spasticity that accompanies it. Also included is a
discussion about the physical therapy that is provided to enhance baclofen therapy.
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CHAPTER ONE
INTRODUCTION

Cerebral palsy affects one to two newborns per 1000 live births in the United
States. 1 The majority of children who are afflicted with this motor disorder experience
some degree of spasticity. The spasticity caused by cerebral palsy (cerebral spasticity)
results in a life-long increase in muscle tone that interferes with voluntary muscle
movements.2 This can often be very painful and disabling to the child, which in turn
affects normal posture, daily activities, and mobility.
Since spasticity is so wide-spread within the cerebral palsy population and
because it affects nearly every aspect of the child's life, an effective treatment program is
necessitated. Traditionally, cerebral spasticity was treated by physical therapists in an
attempt to maintain range of motion, prevent defonnities, and promote proper posture and
daily functions. l Today, surgical procedures such as selective dorsal rhizotomies~ oral
medications like dantrolene, diazepam, and

baclofen~

intramuscluar injections of

botulinum toxin~ and intrathecal baclofen have been used in addition to physical therapy
to help aid in the reduction of spasticity. 1 Baclofen, both oral and intrathecal, is one of
the most common medications used for the treatment of spasticity in children with
cerebral palsy.3
The purpose of this literature review is to discuss in detail cerebral palsy,
spasticity, and the use of oral and intrathecal baclofen in the treatment of cerebral
1

spasticity. This review draws information from current literature and summarizes the
material as it relates to physical therapy. It will answer the question how is baclofen used
in the treatment of spasticity in children with cerebral palsy to enhance a physical therapy
rehabilitation program. In quest of answering this question, more related inquiries may
arise, such as: What exactly is cerebral palsy? Who does it affect? What is spasticity?
How does spasticity affect the body? Can spasticity be treated? What kinds of treatments
can be used to manage spasticity? Who is a good candidate for baclofen therapy? What
kind of research has been done on baclofen? How can physical therapy help manage
spasticity? Does the reduction of spasticity improve functional performance?
In an effort to address these questions, this literature review is presented in five
chapters. Chapter two defines cerebral palsy as a non-progressive movement disorder
caused by an injury to the brain occurring before, during, or shortly after birth. It
describes the incidence of cerebral palsy and stresses how common it is amongst
children. Several factors are listed as possible causes in an attempt to explain the
etiology of cerebral palsy. A system for categorizing the disabilities involved with this
disorder is systematically described. It will illustrate how cerebral palsy is classified and
the related disorders that may accompany it. Finally, chapter two will briefly present the
common treatment approaches that are currently being used to address the plethora of
disabilities that stem from cerebral palsy.
Chapter three covers spasticity, specifically cerebral spasticity secondary to
cerebral palsy. It defines the anatomy of this disorder as an increase in muscle tone and
explains how it is manifested within the body. The Ashworth Grading Scale for
Spasticity is described in this chapter to increase that understanding of how the level of
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spasticity is determined in the child. A discussion follows of what level and when
spasticity treatment is appropriate. Once it is determined that the spasticity within the
child is disabling enough to be treated, a type of treatment can be decided upon. Chapter
three provides a list of treatment options that are available for the child and which ones
are most popular. The importance of enhancing spasticity treatment is also stressed,
especially for the physical therapist's role in supplemental care. A description of how
physical therapy optimizes and contributes to the management of cerebral spasticity is
included.
Chapter four covers the topic ofbaclofen. The pharmacology of the drug is
explained to clarify how it works within the central nervous system. Specific information
about oral and intrathecal baclofen is presented here. The administration of oral baclofen
and the involvement of the blood-brain barrier are described. This is contrasted with a
description of intrathecal baclofen and how its administration bypasses the blood-brain
barrier by being directly delivered to the site of action. An explanation of how the
baclofen pump is implanted and how it functions is also provided, along with a complete
description of the adverse side effects and possible complications that may accompany
the use ofbaclofen. A list of advantages and disadvantages of each method of delivery is
noted to help clarify which type is most appropriate for which patients.
The last chapter of this literature review summarizes the information that has been
presented. It reports the results of existing research on baclofen therapy and discusses
their findings. It provides answers to the original research questions and links the use of
baclofen to physical therapy treatments for spastic cerebral palsy.

3

This review focuses on educating physical therapists, other health professionals,
and interested readers on the use ofbaclofen in treating spasticity in children with
cerebral palsy. It will help the individuals participating in the management of spasticity
understand why and how each method ofbaclofen therapy works. This understanding
will help guide the rehabilitation of children with spastic cerebral palsy.

4

CHAPTER TWO
CEREBRAL PALSY

Incidence
Cerebral palsy is not a disease. Rather it is a category of disabilities, with an
onset in early childhood, stemming from chronic non-progressive disorders of movement
and posture. 4 These disabilities are the result ofa static lesion to the developing brain
acquired either before birth, during birth, or within the first five years of life. S Its
occurrence has been reported to range from l.5 to 5.0 cases per 1000 persons. 4,S,6,7 The
differences in the range can be attributed to the new advances in technology and care of
premature infants. There has been a decrease in certain types of cerebral palsy due to
better prenatal treatments. The incidences of other types of cerebral palsy have increased
due to the survival of more premature infants. 5,6

Etiology
Ratcliffe6 explained the etiology of cerebral palsy by describing two separate time
periods when different influences on the brain can have a significant impact on its
development. Influences that cause damage to the brain either during gestation or the
delivery process are termed congenital cerebral palsy. Acquired cerebral palsy is caused
by influences that occur after birth and within the first few years of life.

5

Eighty-five percent of the cases of cerebral palsy are congenital. 6 Prenatal factors
such as genetics, viruses and infections, Rh incompatibility between mother and fetus,
drugs and alcohol, and fetal positioning can cause brain damage. Any of these incidents
can disrupt the delicate environment between mother and child and can result in cerebral
palsy. Events during the delivery process and shortly after birth may also contribute to
cerebral palsy.6 The risk factors include premature birth, prolonged labor, breech birth,
prolapsed umbilical cord, birth trauma, severe jaundice, and poor nutrition. 6 In many of
these ·cases, a lack of oxygen to the brain is the cause of the damage. Other possible
sources of cerebral palsy in infants include ischemia, lung diseases, and heart conditions. 4
Abnormal neonatal signs and low Apgar scores may serve as indicators of cerebral
palsy.4
The remaining 15% of cerebral palsy cases are acquired.6 Events occurring after
birth or within the first few years of life disrupt the brain while it is still developing
rapidly. Post-natal infections, such as meningitis or encephalitis, are the leading cause of
acquired cerebral palsy, comprising 60% of the cases.6 Another 20% of the cases are
attributed to head injury or trauma from motor vehicle accidents and child abuse. 6 Other
possible causes include, but are not limited to, near drowning accidents, cardiac arrest,
cerebral vascular accidents, brain tumors, anemia, and lead exposure.6

Classification
Once a child is diagnosed with cerebral palsy, a classification of disabilities is
made. Classifications are made both anatomically, depending on what extremities are
involved; and physiologically, depending on the location of the brain lesion and the type

6
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of motor disorder present. When only one extremity is involved, the cerebral palsy is
classified as monoplegia. 5,8 Paraplegia involves only the lower extremities. Ifboth the
upper and lower extremities are involved, it is classified as either quadriplegia (all four
limbs are equally involved), diplegia (all four extremities with the legs more involved
than the arms), or hemiplegia Gust one side of the body is affected).8 Hemiplegia is the
most common form of extremity involvement in cerebral palsy.6
The type of motor disorder that is present with cerebral palsy is dependent upon
the area of the brain that is affected. When the motor cortex is injured, the resulting
8
abnormality is spastic cerebral palsy. If other areas of the brain, such as the basal
ganglia or the cerebellum, are involved, the result is dyskinetic cerebral palsy.4
Spastic cerebral palsy, the most common type, affects 50 - 75% of the children
with cerebral palsy. 1,2,3,7,9,10,11,12 Spasticity is characterized by a velocity dependent
increase muscle tone. 6,7,13,14,15 Children with spasticity often find voluntary movement
difficult or impossible. 3 Ifvoluntary movement is possible, it is usually demonstrated
with stiff, jerky motions of the body.16 Specific aspects of spasticity will be discussed in
greater (detail in chapter three.
Abnormal synergy patterns, mass patterns of movement in which muscles are
abnormally linked together in predictable directions, are often seen in patients with
spastic cerebral palsy. 17 These patients most often exhibit a flexion synergy pattern,
\

lin~ed muscles are held in a flexed pattern. But extension synergies, where the
~scles are all held in extension, are not uncommon.7
where

Spasticity can also lead to poor and abnormal postures. This can result in muscle
contractures, scoliosis, and orthopedic impairments.4,6 Pain may also accompany the
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increase in muscle tone and can contribute to the interference with motor development.6,7
These characteristic factors usually lead to a decrease in the initiation, speed, and strength
of movement; poor balance and coordination; increased energy requirements; and an
overall decrease in stability.6
Dyskinetic cerebral palsy involves intermittent tension of trunk or extremities and
a variety of uninhibited movement patterns. 8 Types of dyskinetic cerebral palsy include
athetosis, dystonia, choreiform movements, ballismus, and tremors. 4 Athetosis is
characterized by fluctuating muscle tone throughout the body and face. 4,6 This is present
in about 114 of all children with cerebral palsy and is characterized by slow writhing
movements observed as the person involuntarily moves between the extreme ranges of
motion. 4,16 Athetosis often develops following a hypotonic infancy.6 Dystonia affects 15
- 25% of persons with cerebral palsy and involves sustained muscle contractions, causing
twisting and repetitive movements or abnonnal postures of the extremities.4,11 This
condition is associated with pain and causes fixed postures and tone changes in the
trunk. 11 Choreiform movements are also present in the face and extremities; however
these movements are characterized by rapid, irregular, and jerky motions of the body.4

Ballismus includes wild flailing or flinging motions of the extremities within a wide
range of motion. Tremors are seen as fine, shaking movements of the head and
extremities. 4
Two more rare types of movement disorders associated with cerebral palsy are

ataxia and rigidity. Ataxic cerebral palsy results from a cerebellar lesion and affects
only affects 5 - 10% of people with cerebral palsy.8,18 Ataxia is characterized by a lack of
proprioception in the joints and hypotonicity in the muscles, affecting the balance and
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coordination of voluntary movements. 4.6 Rigidity indicates a severe brain lesion at the
level of the brain stem.6.8 It can be demonstrated in several different forms including
extension of all extremities, flexion ofthe arms and extension of the legs, or with a "cogwheeled" affect (involves the muscles on both sides of the joint which release and catch
intermittently with passive movement).4.6 Unlike the tone present with spasticity, rigidity
6
is not velocity-dependent and it remains the same throughout the range.
Mixed cerebral palsy is a condition that can include several different
combinations of movement disorders either present at the same time or at different stages
throughout development. 4.6.16 Nearly 25% of persons with cerebral palsy have mixed
disorders.16 Hypotonicity (low muscle tone) is often a precursor of spasticity or athetosis
and is generally present in conjunction with ataxia.4•6

Related Disorders
In addition to the movement abnormalities, children with cerebral palsy often
exhibit related disorders. 4•5•6 Mental retardation has been reported in 50 - 75% of
children with cerebral palsy.6 Further examination found that some types of cerebral
palsy have a greater distribution of cognitive impairments. Children with quadriplegia
were found to have mental retardation 60 - 65% of the time. 5 Seizure disorders are also
common among the cerebral palsy population. 5•6 It was found that nearly 30% of
children with quadriplegia have seizures and those with acquired cerebral palsy were at
an increased risk.
Hearing and vision impairments often affect children with cerebral palsy. Vision
problems are seen in approximately 50% of the cases because proper vision relies on the
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motor ability of the eye muscles.6 Speech deficits are present in 50% of the children with
cerebral palsy.6 This is also due to motor abnormalities in the musculature needed to
perform speech patterns properly. Sensory and behavioral disorders are often present
due to damage in their respective areas in the brain. 6

Treatment
Cerebral palsy is a motor disorder that is characterized by several different forms
and combinations of disabilities. Some treatment in necessary, whether the child is
severely disabled or just has mild impairments. Management of cerebral palsy can take
on several different approaches, although the main focus is usually on the management of
6
the central motor disorder. Related disorders that accompany central motor disorder
may be treated with additional specialized treatments.
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CHAPTER THREE
SPASTICITY

Spasticity is present in approximately 2/3 of the children with cerebral
palsy.l,2,3,7,9,I0,l1,12 Spasticity is characterized by a velocity-dependent increase in tonic
stretch reflexes or muscle tone in response to quick stretching. 13 It is often associated
with hyperreflexia, hypersensitivity to sensory stimuli, clonus, weakness, persistent
primitive reflexes, and abnormal posturing and movement of the extremities.6,7,14 This
increase in muscle tone can occur in any voluntary muscle of the body causing awkward,
difficult, and often painful movements. 3 In tum, this condition interferes with motor
development, habilitation, and activities of daily living.7

Anatomy of Spasticity
Spasticity is the result of an injury or disease; in cerebral palsy it is the result of a
brain injury and is classified as cerebral spasticity. Spinal spasticity is caused by an
insult to the spinal cord as in a spinal cord injury or multiple sclerosis.

1

Cerebral

spasticity results in involuntary muscle tightness and stiffness due to the inability of the
damaged brain to send messages to the spinal cord instructing it to release the relaxing
chemical called y-aminobutyric acid (GABA).3 Without GABA, the excitatory
interneurons within the spinal cord are not suppressed, allowing them to fire
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continuously. Muscles receive excitatory information and contract repeatedly producing
stiff or spastic muscles. IS

Grading Spasticity
The level of spasticity in a child with cerebral palsy can range from very mild to
extremely severe. IS Physicians, physical therapists, and other health professionals often
use the Ashworth Muscle Tone Scale to determine the level of spasticity and make
decisions regarding the type and level of treatment that would be most appropriate for the
child.17,19 Ashworth's scale grades the muscle's resistance to passive stretch (spasticity)
on a five-point ordinal scale.13 MacKenzie and Charlson found this scale to have high
validity because it measures spasticity when the muscle is moved passively. 13,19,20 The
Ashworth Scale for grading spasticity in shown in table 1.

Table 1. Ashworth's Scale for Grading Spasticity 13,17,19

Grade

o
1

2
3
4

Description
Normal muscle tone
Slight increase in muscle tone, giving a 'catch' when the limb is moved
in flexion or extension
More marked increase in muscle tone through the range of motion, but
the limb is easily flexed
Considerable increase in muscle tone, passive movement is difficult
Limb rigid in flexion or extension

Bohannon and Smith 13 introduced a modification to the Ashworth Scale in a study
in 1985. An intermediate grade of 1+ was added to describe a slight increase in muscle
tone, manifested by a catch, followed by minimal resistance throughout the remainder
12

(less than one half) of the range of motion. 13 This was created to reduce the clustering
effect around the middle grades. I7 Testing of the modified Ashworth Scale by Bohannon
and Smith I3 indicated a high interrater reliability score.

When is Treatment Appropriate?
Treatment for cerebral spasticity is recommended when it is disabling to the
child. 7 Disabilities occur when the spasticity interferes with normal daily activities or
caregiving; is painful for the patient; produces abnormal posture; or when it results in
contractures and/or a loss of joint range ofmotion. 3,15 However, not all spasticity needs
to be treated, because not all spasticity is detrimental. 21 In some cases, patients use their
spastic muscles to compensate for motor deficits. Spasticity in the lower extremities can
help maintain leg extension during standing, transferring, and walking?2 Increased tone
in the trunk musculature can aid a child in sitting in an upright posture. 23 There has also
been documentation of spasticity improving vascular flow to the muscles and maintaining
muscle bulk. 24

/1 Treatments of Spasticity
J

Spasticity cannot be cured; rather, it is managed. 15,25 Management is attempted
with various types and combinations of treatment methods. A single plan of treatment
for spasticity will not be effective for all children with cerebral palsy. Spasticity is
manifested differently in each individual; thus therapy must be tailored for the child to
address his/her unique functions and disabilities.26
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The ultimate goal of spasticity treatment is to either increase the patient's
independence with ADLs and/or to ease caregiving responsibilities. IS Current treatments
that are available for the management of cerebral spasticity are oral medications such as
baclofen, diazepam, and dantrolene; intramuscular injections of botox; infusion of
intrathecal baclofen; and an orthopedic surgery called selective dorsal rhizotomy.3
With each treatment comes a diverse set of indications, contraindications, side
effects, and success rates. To determine which treatment would be most appropriate, a
multidisciplinary team-- usually consisting of physicians, physical therapists,
occupational therapists, nursing staff, social workers, and the family-- will collectively
evaluate the child. 7,ls Together they will define the tone abnormality, the severity of the
disability, and recommend the treatment. IS
Currently, baclofen (the focus of this review) is a widely used medication for the
treatment ofspasticity.3 Baclofen can be administered both orally and intrathecally.
Each method of delivery produces varying degrees of effectiveness and may be
accompanied by different adverse effects.

Enhancing Spasticity Treatment
The treatment of spasticity will not be completely successful unless it is followed
by supplemental care. IS Supplemental care is usually provided by a variety of
professionals from a multidisciplinary team. The team usually consists of the physician,
a physical therapist, an occupational therapist, a speech/language pathologist, a
psychologist, a nurse, a social worker, and the family. Together they work to assist the
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child in achieving his/her highest functional status. 7 Individuals from each discipline will
focus on their areas of expertise to optimize the impact of spasticity treatment. IS

An important aspect of spasticity treatment is to begin when the children are
young. Childhood is the time when most motor development takes place. In fact, most
children reach their expected functional capacity by the time they reach school age. 4,IS If
spasticity can be reduced early, this will minimize the adaptations the children learn to
compensate for their motor deficits. IS Early intervention can also minimize muscle
contractu res and bone deformities, thus reducing the need for orthopedic surgeries. 4,27

Physical Therapy's Role
Physical therapy plays a major role in enhancing spasticity treatments. IS Both
before and after the patient has received medication or has undergone a spasticity
reduction procedure, physical therapists often aid in the management process. IS Physical
therapy is aimed at making normal movements easier, inhibiting abnormal motor
functions, minimizing posture deficits, and preventing deformities. 7,2s The ultimate goal
of physical therapy is to decrease the degree of disability in the child?S
Before the initial spasticity treatment, a physical therapist will evaluate the child's
gross motor functions, often using the Gross Motor Function Measure (GMFM)
scores. 1S,28 This evaluation includes assessment of tone, active and passive range of
motion, strength, coordination, and functional abilities, such as sitting, standing, rolling,
and ambulation?S These findings assist the therapist in recommending the type of
treatment that would be most appropriate in reducing the child's spasticity.

15

Once the treatment has begun, physical therapy will work with the children to
teach them how to function with the reduction of spasticity. IS Depending on the extent of
the child's disability, the therapist may provide adaptive equipment such as wheel chairs,
walkers, braces, and positioning aids to help the child achieve independent mobility.2s
Besides mobility, some other concerns of physical therapy include helping the
children strengthen their weak muscles and improving their overall functionys,2s This is
accomplished by incorporating a variety of activities into a physical therapy regime that
often includes range of motion exercises, strengthening exercises, functional activities,
and balance training. IS

16

CHAPTER FOUR
BACLOFEN
Baclofen (trade name: Lioresal®) was introduced in the United States in 1967 and
then approved in the early 1970's as a medication for the management of muscle
spasticity?9,30 Originally, baclofen was intended for use as an anticonvulsant; however
during the evaluation of the drug's effectiveness, baclofen was discovered to be more
effective at reducing spasticity.} Baclofen acts on the central nervous system (CNS) to
produce muscle-relaxing effects as well as to relieve muscle spasms and cramping caused
by medical conditions such as multiple sclerosis, traumatic brain injury, and cerebral
palsy.3l Antispasmodic action is now the main indication for the drug. 29 Albright
summarized from a study completed by Van Hemert that spasticity was reduced in 16 of
the 18 patients treated with baclofen, while only 1 of the 17 patients treated with a
placebo had a reduction. }

Pharmacology
The precise action ofbaclofen is not yet fully understood.32 Baclofen is thought
to act as an agonist, or replacement, of the inhibitory neurotransmitters y-aminobutyric
acid (GABA).l,2,30,33 A comparison of the chemical structure of GAB A and baclofen is
shown in figure 1. GABA is muscle-relaxing chemical found throughout the central
nervous system (CNS). Children with cerebral palsy and other brain injuries are GABA
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deficient. 1,34 As an agonist, baclofen is allowed to combine with membrane receptors
that are normally influenced by GABA. 22,35 There are two types of GAB A receptors
found in the CNS: GABA-A and GABA-B receptors. Baclofen has a direct effect on
GABA-B at spinal cord level by impeding the release of the excitatory neurotransmitters
used to stimulate a muscle contraction. 1,9,22,24,3S
It is important for physical therapists and other health care professionals who

work with patients on baclofen treatment to understand the mechanism of action.
Awareness of how baclofen affects the patient will aid therapists in making educated
decisions about rehabilitation programming.

GABA

Socloten

Figure 1. Chemical structure of GAB A and baclofen. 1

Oral Baclofen
Oral baclofen is taken in tablet form. Once ingested into the body, it is quickly
absorbed from the gastrointestinal system into the blood stream.1,30 From the blood
stream the medication must reach GABA receptor sites within the spinal cord.2,30 To do
this, the drug must first cross the blood-brain barrier. This is often difficult because this
barrier is intended to keep drugs and other harmful substances from entering the cerebral
18

spinal fluid (CSF). High concentrations ofbaclofen must be present in the blood so that
it can push the drug down the concentration gradient, through the blood-brain barrier, and
into the CNS?O
The antispasmodic effects of oral baclofen vary considerably among children with
cerebral palsy. 1,9,30 Most children begin baclofen therapy at doses of 5 - 10 mg/day,
increasing the dose until a total of20 - 60 mg is taken per day. Some children have
required up to 160 mg/day for an observable effect.
Peak serum levels occur within the body approximately 2 - 3 hours after ingestion
and the drug has half-life of 3 - 4 hours. 1 The daily amount must be divided into several
different doses in order to keep peak serum levels within the body constant.

Intrathecal Baclofen
The Food and Drug Administration approved intrathecal baclofen for the
30
treatment of cerebral spasticity in June, 1996. Intrathecal baclofen is usually prescribed

when oral baclofen is unsuccessful in controlling spasticity or when the patient
experiences disabling side effects, such as extreme drowsiness or fatigue, from the oral
drug. 22,33 However, it is not necessary that oral baclofen be given unsuccessfully before
choosing intrathecal baclofen.

10

Intrathecal baclofen takes the same action as oral baclofen except that it is
administered directly into the CSF. 1,2,3,9,10,l1,12,21,23,27,29 This is an advantage over oral
baclofen because it allows the drug to bypass the blood-brain barrier and to have
immediate access to the GABA receptors at the spinal cord level. 1,22,23 This reduces the
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systemic effects the drug has on the body?2 The adverse effects ofbacIofen will be
discussed later.
Intrathecal baclofen is delivered to the patient from a battery operated pump that
is implanted within the abdominal wall. 30 The pump resembles a hockey puck and
weighs about 6 ounces?·30 A small, subcutaneous catheter runs from this device to the
lumbar intrathecal space, where the medication is consistently delivered into the CSF.7

An illustration of the bacIofen pump and catheter is shown in figure 2. The catheter is
usually inserted around the L4 - 5 interspace?2 The placement of the pump within the
body is shown in figure 3.

Figure 2. Illustration ofbacIofen pump and catheter.1.3,23.33

The pump communicates with an external computer via radiotelemetry.7
Currently, SynchroMed pump, by Medtronic, Inc., is the only commercially available
implantable pump that is externally programmable. 10.30 The external computer can read
information stored within the pump concerning the amount of drug remaining in the
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pump, the concentration of the drug, and the rate at which the medication is being
delivered to the patient. 30

Figure 3. TIlustration of pump placement within the body.1,3,23,33

Once the baclofen is introduced into the CSF, it travels up through the spinal cord,
declining progressively in concentration. 1,3 Once the medication has reached T2 it is
about 43% the concentration it was at T12.22 Spasticity in the lower extremities is more
affected by the drug than the upper extremities and the brain. 22
Intrathecal administration of the drug requires a smaller dosage to achieve larger
CSF concentrations. 22 The drug is available in two concentrations 500 or 2000 Jlg/ml and
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the physician will determine which is appropriate. Dosages range from 150 - 350
~g/day? The half-life of intratheeally administered baclofen is 5 hours. 1

The pump needs to be refilled every 1 - 3 months depending on the rate of
infusion. 7 This is done via a percutaneous injection into the pump.7 An audible beep will
be heard if the volume of the baclofen drops below a certain point. 3D Once the battery
gets low, usually after 4 - 5 years, the pump will need to be replaced with a fresh one. 1
The patient must be thoroughly screened prior to implantation to determine if
he/she would be a good candidate for intrathecal baclofen. 7 This is detennined by
injecting a test bolus ofbaclofen into the lumbar CSF. A physical therapist, or another
trained professional, will then grade the patient's muscle tone at 2, 4, 6, and 8 hours
following the procedure.1,7 If a significant reduction in spasticity (at least a 1 - point drop
on the Ashworth muscle tone scale) is observed, and the patient is free of adverse
neurological effects, the patient is recommended to start the therapy. 7 The trial dose can
be effective for detennining success of intrathecal baclofen, but it will not necessarily
predict the outcome. 3 If the 'patient does not respond to the treatment or if complications
arise, the implantation is completely reversible and the hardware can be removed without
permanent damage to the child. 7

Side Effects and Complications of Baclofen
This research of current literature has found that the side effects of oral baclofen
and intrathecal baclofen are very similar.1,3,9,lO,12,22,23,33 The side effects ofbaclofen often
include drowsiness and lethargy, fatigue, muscle weakness, nausea, dizziness, dipoplia,
diarrhea, urinary retention or incontinence, and dry mouth.31 ,32,33 Oral baclofen tends to
22

have an increased incidence of side effects due to the higher doses at which it is
administered. 22
Generally only minor complications arise when the drug is given within the
3
therapeutic range?O Most of these can usually be minimized when the dosage is reduced.
According to Abbott30, more serious complications occur when the medication
levels exceed what is appropriate for the patient. With this type of overdose situation
extreme sleepiness can lead to respiratory depression and even coma. If the drug is
discontinued in time and the patient is put on a ventilator, most long-term effects can be
avoided. 30
\!--brupt withdrawal from baclofen should be avoided if at all possible. Sudden
absence of the drug can cause serious hazards such as hallucinations and seizures, and
thus can subsequently be a threat to the child's life.31 ,32,33 Except for when overdose
situations occur, baclofen should be reduced slowly.30 The physician who prescribed the
drug would be the best at recommending how to gradually decrease the dosage.32
According to Campbell et al,22 intrathecal baclofen therapy carries a few
additional risks to oral baclofen. Since intrathecal baclofen requires an invasive surgical
procedure, it involves the risk of anesthetic exposure.22 The surgery also increases the
risk of infection at the site of incision. Mechanical hardware complications can include
catheter kinks, blockage or dislodging of the catheter, and/or pump failure?3
Manufacturers of the earliest pumps admitted to having a 3 - 7% failure rate; however
manufacturers claim the newer models are more reliable and equipped with safety
features. If the hardware fails, it needs to be replaced surgically. Kinks in the catheter
and other disruptions are common, but they can be easily fixed under local anesthesia. 22
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Tolerance to both oral and intrathecal baclofen has been noted in some patients on
long tenn therapy.1,23 However, this has not been a significant clinical concern because
of its infrequency. I

Advantages and Disadvantages
One advantage that oral baclofen has over intrathecal baclofen is that it is a noninvasive treatment. 22 Oral baclofen is taken by mouth and therefore does not require
surgical intervention. As explained above, intrathecal baclofen carries the additional
risks that accompany the surgical procedure used to implant the pump?3 When patients
are not in good enough health to endure this type of procedure, oral baclofen may be the
better route of treatment. Although intrathecal baclofen carries these additional risks, it is
totally reversible and the pump and hardware can be removed without pennanent damage
to the child. 7
Another advantage oral baclofen has over intrathecal, is that the intrathecal
baclofen pump needs maintenance.7 As stated previously, the pump needs to be refilled
with the medication every 1 - 3 months and it needs to be replaced every 4 - 5 years as
the battery wears out. 1,7 There is also the slight chance that the mechanical hardware
within the pump or catheter could become displaced or fail. 23
The benefits of intrathecal baclofen come with the method of delivery and the
amount of drug concentrations administered. I First of all, intrathecal baclofen is
delivered directly to the site of action within the CSF; therefore it does not need to cross
the blood-brain barrier to be available to the GABA receptors. 7 This allows the drug to
be administered in smaller doses while still achieving relatively larger CSF
24

concentrations. 22 It is suggested that intrathecal baclofen has a greater efficacy due to its
tenfold higher CSF concentrations as compared to oral baclofen.
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Oral baclofen doses

would need to be 100 times higher to produce a tenth of the concentration achieved
intrathecally?2 All of these factors reduce the systemic effects the drug has upon the
body.22
Another advantage of intrathecal baclofen is that it provides a steady flow of
medication, thus avoiding the fluctuation of serum levels within the body.7 The pump
has precise programming capabilities to produce the optimum in spasticity reduction
effects. 7 It can be programmed to change dosage levels throughout the day to address the
needs of alternating muscle tone. For instance, a higher dose can be administered during
the day when spasticity is more prevalent and a lower dose at night when the patients are
sleeping and their spasticity is naturally decreased. 7 A lower dose can be given during
the day when the patients uses their spasticity for maintaining leg extension during
ambulation, with higher doses at night to reduce spasms that may occur at night and
disturb sleep.22
One important consideration that must be made before deciding on the
appropriate method ofbaclofen treatment is that of the family ' s geographical location.
Intrathecal baclofen pumps are only implanted and refilled in certain locations. If the
family is not located near one of these sites a significant amount of travel may be
necessitated to keep proper maintenance of the pump. This can be a disadvantage of
using intrathecal baclofen. A chart of the specific advantages and disadvantages of oral
baclofen are listed in table 2. The advantages and disadvantages of intrathecal baclofen
are listed in table 3.
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Table 2. Advantages and Disadvantages of Oral Baclofen

Advantages
Does not require surgical intervention

Disadvantages
Must be taken in large doses to be effective

Maintenance is not required (no hardware)

Drug must cross blood-brain barrier

Prescription can be refilled anywhere

Increased side effects

Table 3. Advantages and Disadvantages ofIntrathecal Baclofen

Advantages
Medication is delivered directly to site of
action; bypasses blood-brain barrier

Disadvantages
Requires surgical intervention to implant
pump

Can be administered in smaller doses

Requires maintenance; e.g. refilling pump,
replacing after battery dies

Provides steady flow of medication

Need to be located close to or travel to
appropriate intrathecal baclofen site for
implantation and refilling site

Decrease in side effects due to lower
dosage

Decisions about which type ofbaclofen therapy would be most appropriate for the
patient are ultimately up to the physician and the family. However, physical therapists
are often involved in the evaluation and assessment of the patients and often recommend
the treatment they believe would be most beneficial for the patient. This is why it is
important to understand the reasoning behind each type of spasticity treatment. It is also
important because the type of treatment given will help guide the therapists in properly
planning the rehabilitation of their patient.
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CHAPTER FIVE
REVIEW OF RESEARCH

The purpose of this review is to present information from current literature on the use of
baclofen in the treatment of spasticity in children with cerebral palsy. To better
understand the function ofbaclofen and how it is used in reducing cerebral spasticity, a
review of cerebral palsy and spasticity is included. The benefits of physical therapy that
provide supplemental care to enhance spasticity treatment are also reported. Even though
there are some differences in how baclofen is administered, both oral and intrathecal
baclofen are effective in treating spasticity in children with cerebral palsy. Several
studies l,2,9,ll,2l,22,26,28,37 supporting this conclusion are summarized below.

Influence of Baclofen in Treating Spasticity in Cerebral Palsy
Oral Baclofen
38
Van Hemert assessed the effectiveness of oral baclofen in a double-blind study of oral
baclofen and a placebo. Van Hemert found that spasticity was reduced in 16 of 18
patients participating in the test group of oral baclofen, while only one of the 17 patients
in the control group who were treated with a placebo experienced a reduction in
spasticity.38 In a similar study, Hattab39 summarized that oral baclofen reduced spasticity
in 80% of the 315 patients examined. The same study also concluded that baclofen was
equal to or better at reducing spasticity then diazepam. 39
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Intrathecal Baclofen
Subsequent reports by Albright and colleagues 1,2,3,9,lO,ll,12,36 have indicated that
intrathecal baclofen is effective in reducing spasticity in children. A study with 37
patients with cerebral spasticity, whose mean age was 14 years, found that the muscle
tone in the upper and lower extremities decreased significantly. This reduction in
spasticity was independent of whether the cerebral spasticity was due to cerebral palsy,
anoxia, trauma, or encephalitis. 1 Another study by Albright et al, 2 detected a significant
increase in the range of motion of the knee following continuous intrathecal baclofen. In
the same study, subjects were tested on their performance on four daily skills:
communication, hygiene, eating, and dressing. They were graded on a scale of 0 to 5 on
each skill and then the grades were averaged. The scores of the subjects on the personal
independence scale increased significantly, rising from 2.06 prior to treatment to 2.75
following two years of treatment. 2
Campbell, et. al.,22 reviewed the effects of intrathecal baclofen on patients with
both spinal and cerebral spasticity. In an informal analysis, this study graded the
patients' ADLs on a functional scale. It was found that there was a 60 - 70%
improvement in patients' transfers, self-care, and mobility, and a 10 - 30% improvement
in quality of life.
37
A study by Latash and Penn studied the effects of intrathecal baclofen upon
voluntary movements. It measured the kinematic/dynamic and electromyographic
(EMG) patterns of voluntary muscle contractions. Latash and Penn37 concluded
intrathecal baclofen improved the selectivity of muscle activation in two patients with
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cerebral palsy and that single joint movements became smoother with a visible increase
in the peak speed of muscle activity.
Penn, Gianino, and York40 reported that two cerebral palsy patients with athetosis
treated with intrathecal baclofen therapy were found to have a decrease in Ashworth
scores by 2 and 2.85 respectively. Similarly, a study examining intrathecal administration
ofbaclofen in patients with spasticity of cerebral origin found a clinically significant
reduction in muscle tone (measured on the Ashworth Muscle Tone Scale) in 9 of the 10
children. 36
Almedia et. al. 28 described a case of an II-year-old boy with spastic diplegia who
was able to discard his orthoses shortly after starting intrathecal baclofen therapy. Hip
and ankle range of motion increased, independence in dressing and transfers improved,
and Gross Motor Functional Measure (GMFM) scores were 7.8% above baseline after
one year on baclofen therapy.28 In a variety of studies, it was found that intrathecal
baclofen effectively reduced spasticity, improved voluntary motions, and improved the
quality of life in children with cerebral palsy. 1,2,3,9,10,11,12,36,37,38,39,40

Conclusion
The reduction of abnormal muscle tone with the aim of improving functional
performance has long been a goal of physical therapy.22 With the aid of spasticity
reduction from baclofen therapy, physical therapists are now able to help children with
cerebral palsy achieve a higher functional status. Physical therapists teach children how
to function with their reduced spasticity. IS This is accomplished by focusing on the
child's abilities and maximizing them so that they are functional for the child.
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Baclofen helps the physical therapist treat patients with cerebral palsy by reducing
spasticity within the body. This decrease in muscle tone enables the child to produce
voluntary muscle movements with less pain and difficulty. Therefore, this allows for the
therapist to work with the child on increasing normal posture, increasing strength in the
muscles, and developing mobility skills. Before the use ofbaclofen (or other spasticity
reducing treatments) was approved for use in treating spasticity in cerebral palsy,
physical therapists focused on the prevention of deformities and contractures. This was
accomplished with range of motion and stretching exercises. The use of orthotics and
assistive devices were also used to promote proper posture. Although these techniques
are still a large part of physical therapy provided today, therapists can now use additional
techniques in the rehabilitation programs due to the increase in the potential of patients.
Thanks to spasticity treatments such as baclofen, instead of just prevention, therapists can
now work with their pediatric cerebral palsy patients to improve functional activities.
Range of motion exercises can be modified from passive to active to increase
independent range. Once spasticity is reduced, strengthening exercises are used to
increase the strength of the muscles that were weakened due to the spasticity. IS
Depending on the level of involvement of disability in the patient, therapists may work
with patients on increasing their independence in daily functions and mobility, or they
may work with patient and caregiver on decreasing the difficulty of caregiving tasks.
Assistive devices such as orthotics or wheel chairs and walkers may either be added, upgraded, or removed completely, depending on the needs of the particular patient. Some
patients who once needed a walker for mobility may be able to discard it due to an
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increase in independent ambulation. Patients who were not able to move independently
previously may be able to add an assistive device to do so.

Answer to the Research Question
How is baclofen used in the treatment of spasticity in children with cerebral palsy
to enhance a physical therapy rehabilitation program?
Baclofen, whether it is delivered orally or intrathecally, is used in children with spastic
cerebral palsy to decrease the high muscle tone or spasticity within the children's
muscles. The reduction of spasticity allows more opportunity for controlled voluntary
movements by patients. This in turn, can lead to an overall increase in children's
functional abilities and quality of life. Physical therapy acts as a supplement to baclofen
therapy or vise versa. Baclofen reduces spasticity and physical therapy increases activity
and independence. Together baclofen therapy and physical therapy work to help children
with cerebral palsy to reach their highest functional status.

Recommendations
Although the studies reviewed have clinically conclusive data measuring several
factors supporting baclofen therapy as an effective treatment in reducing spasticity in
children with cerebral palsy, research needs to continue. 1,2,9,11,21,22,26,28,36,37 Since the
FDAjust recently approved the intrathecal pump for use in cerebral palsy children in
1996, it would be beneficial to determine if intrathecal baclofen therapy is effective over
time. Research of long-term oral and intrathecal baclofen therapy in children with
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cerebral palsy needs to be followed closely to determine if these treatments are safe and
effective.
Another component that would be useful in evaluating the effectiveness of
baclofen and physical therapy in the management of cerebral spasticity would be a
standardized measurement for grading spasticity reduction. This type of measurement
tool would increase the reliability and validity of long-term baclofen studies that used
muscle tone grades to reflect effectiveness of spasticity treatments.
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